← Back to Search

Glucagon-like peptide-1 receptor agonist

Semaglutide for Obesity (STABLE Wt Loss Trial)

Phase 4
Waitlist Available
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 18-70 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up s1: change from baseline to weeks 20, 40, and 60, and measures at week 72; s2: week 72 endpoint controlling for s1 baseline
Awards & highlights

STABLE Wt Loss Trial Summary

This trial will study the effects of semaglutide, a weight-loss medication, on eating behavior and appetite. All participants will receive diet and exercise counseling, and will be prescribed semaglutide or placebo for 72 weeks.

Who is the study for?
Adults aged 18-70 wanting to lose weight, with a BMI ≥ 30 or ≥ 27 with obesity-related health issues. Must not be pregnant, able to consent, and plan to stay in Philadelphia for the study duration. Excludes those with uncontrolled diabetes or hypertension, recent pancreatitis or cancer history, severe psychiatric disorders, recent weight loss drugs use, and certain cardiovascular conditions.Check my eligibility
What is being tested?
The trial tests if semaglutide affects appetite and eating habits over time compared to a placebo. Participants also receive lifestyle advice on diet and exercise. Semaglutide is an FDA-approved medication for weight loss administered subcutaneously for 72 weeks alongside behavioral treatment.See study design
What are the potential side effects?
Semaglutide may cause digestive issues like nausea or constipation, headaches, fatigue, risk of low blood sugar levels (hypoglycemia), potential thyroid tumors (rare), gallbladder problems like gallstones, inflammation of the pancreas (pancreatitis), and possible allergic reactions.

STABLE Wt Loss Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 70 years old.

STABLE Wt Loss Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~s1: change from baseline to weeks 20, 40, and 60, and measures at week 72; s2: week 72 endpoint controlling for s1 baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and s1: change from baseline to weeks 20, 40, and 60, and measures at week 72; s2: week 72 endpoint controlling for s1 baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Ad libitum energy intake (kcal) during a buffet lunch meal (4 hrs after standardized breakfast)
Secondary outcome measures
Explicit responsiveness to the food environment measured by the summary score of the Power of Food Scale (15-item version)
Global subjective appetite (e.g., hunger, fullness, food preoccupation) over the past week measured using the Control of Eating Questionnaire (COEQ)
Implicit food wanting of high-fat, savory foods measured using the Leeds Food Preference Task
+1 more
Other outcome measures
Body image satisfaction (Body Satisfaction Scale)
Body weight (kg)
Drive for thinness (Eating Disorder Inventory [EDI])
+11 more

STABLE Wt Loss Trial Design

2Treatment groups
Active Control
Group I: Behavioral Treatment + PlaceboActive Control2 Interventions
Behavioral treatment (lifestyle modification counseling for weight loss) plus placebo
Group II: Behavioral Treatment + MedicationActive Control2 Interventions
Behavioral treatment (lifestyle modification counseling for weight loss) plus semaglutide

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,000 Previous Clinical Trials
42,879,968 Total Patients Enrolled
87 Trials studying Obesity
72,347 Patients Enrolled for Obesity
Novo Nordisk A/SIndustry Sponsor
1,513 Previous Clinical Trials
2,414,909 Total Patients Enrolled
141 Trials studying Obesity
131,918 Patients Enrolled for Obesity

Media Library

Obesity Research Study Groups: Behavioral Treatment + Placebo, Behavioral Treatment + Medication

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the combination of Behavioral Treatment and Medication gained regulatory approval?

"The safety and efficacy of Behavioral Treatment + Medication has been evaluated, with a score or 3 out of 3 given due to the completion Phase 4 trials. This indicates that this treatment is approved for use."

Answered by AI

Is this trial open to participants aged over twenty-five?

"As per the requirements of this trial, only individuals aged between 18 and 70 are eligible to participate. For those younger than 18, there are 202 other studies available; whereas for persons 65 years or older, 596 alternative trials may be viable options."

Answered by AI

Is this research endeavor open for participation?

"Affirmative. Clinicaltrials.gov has documented that this clinical study, first posted on July 26th 2022, is actively enrolling patients. The recruitment goal for the trial stands at 120 individuals from a single medical centre."

Answered by AI

What is the highest quantity of persons involved in this investigation?

"Indeed, according to clinicaltrials.gov the trial is actively recruiting patients. It was first posted on July 26th 2022 and has been updated as recently as September 19th 2022. This research requires 120 participants from a single medical site."

Answered by AI

Who else is applying?

What state do they live in?
Georgia
Pennsylvania
New Jersey
What site did they apply to?
University of Pennsylvania Center for Weight and Eating Disorders
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
2
0
3+

Why did patients apply to this trial?

To lose weight. In four months I have gained 40 pounds due to lung issues caused by COVID and heart failure. I need these weight off.
PatientReceived 2+ prior treatments
I always have a constant snack and food seeking drive in my brain. I have heard semaglutide quotes that down. I would love to know if it could help along with healthy eating and exercise.
PatientReceived 1 prior treatment
I have tried absolutely everything and nothing works. The only thing that did work, my insurance didn’t cover and I couldn’t afford to pay it any longer which was the wegovy. My only problem is that I’m obese, no other factors my A1C is 5.8, and my BMI is high, which is why I need help,.
PatientReceived 1 prior treatment
I have been trying to lose weight for years. I was recently Dec/Jan 2022/23, using Wegovy, my insurance wouldn’t pay for it since it was for weight loss and I couldn’t afford to pay out of pocket. I need help. I don’t qualify for any studies because I don’t meet any criteria since I only obese.
PatientReceived 2+ prior treatments

What questions have other patients asked about this trial?

Am I able to do this remotely through testing with LabCorp? Do you have any other pilot studies in the Louisville Kentucky area?
PatientReceived 1 prior treatment

How responsive is this trial?

Most responsive sites:
  1. University of Pennsylvania Center for Weight and Eating Disorders: < 24 hours
Average response time
  • < 2 Days
Typically responds via
Email
Phone Call
Recent research and studies
clinicaltrials.govStudy
Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
2022. "Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05548647.
~48 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top